Event Schedule Three

2022 New Zealand Melanoma Summit > Event Schedule Three
Day 1 Agenda

First Day

8:30 am
10.00 am

Opening session

Opening address
Guest speaker

2022 Melanoma Summit overview
Dr Chris Boberg, Chair 2022 New Zealand Melanoma Summit Planning Committee and Co-Chair, MelNet

Patient challenge
Terence Walsh, Patient representative

Melanoma in the New Zealand cancer landscape
Dr Chris Jackson, Medical Oncologist Southern District Health Board, Senior Lecturer, University of Otago and Chair of Clinical Assembly Te Aho o Te Kahu - Cancer Control Agency

Quality Statements for to Guide Melanoma Diagnosis and Treatment in New Zealand
Dr Richard Martin, Surgical Oncologist, New Zealand Melanoma Unit, Waitemata District Health Board and Chair Melanoma Quality Statements Working Group
10.30 am
11.40 am

Session 1: Epidemiology and primary prevention

Epidemiological trends in melanoma
Professor David Whiteman, Deputy Director, Head of Cancer Control Laboratory and Coordinator, Melanoma and Skin Cancer Research Centre, QIMR Berghofer Medical Research Institute, Queensland, Australia

What is happening about sunscreens in New Zealand?
Jon Duffy, Chief Executive, Consumer New Zealand
Dr Louise Reiche, Dermatologist, Kauri Healthcare Palmerston North and Immediate Past President, New Zealand Dermatological Society Incorporated 

My story
Todd Muller, Patient representative

Questions and discussion
11:40 am
12:30 pm

Session 2: The economics of the skin cancer epidemic

The escalating economic burden of skin cancer to Government
Associate Professor Louisa Gordon, Group Leader Health Economics, QIMR Berghofer Medical Research Institute

A private perspective
Dr Stephen Child, Chief Medical Officer, Southern Cross

Questions and discussion

Session 2 kindly sponsored by La Roche-Posay

1.30 pm
2.45 pm

Session 3: Early detection

Early detection saves lives: Our story
Chris and Judy Bailey, Patient representatives

Settling the debate on skin cancer screening
Professor David Whiteman, Deputy Director, Head of Cancer Control Laboratory and Coordinator, Melanoma and Skin Cancer Research Centre, QIMR Berghofer Medical Research Institute, Queensland, Australia

The evolution of early detection, dermatoscopy and artificial intelligence
Professor Cliff Rosendahl, Course Coordinator of the Master of Medicine (Skin Cancer) Programme, University of Queensland, Australia
Adjunct Associate Professor Amanda Oakley, Dermatologist, Waikato District Health Board

Questions and discussion

Session 3 kindly sponsored by Skin Cancer College of Australasia

2:45 pm
3.30 pm

Session 4: Concurrent breakout session 1

Breakout 4A - Creating sun protective environments
Research shows that New Zealand does not have enough shade in public spaces. In this session, Linda Buxton (Health Promotion and Advocacy Otago Southland Division, Cancer Society of New Zealand) will highlight efforts to create sun protective public environments which utilise shade as a sustainable and equitable way to reduce UV exposure.

Session 4A kindly sponsored by Cancer Society of New Zealand and SunSmart

Breakout 4B - Dermatoscopy in action
In this session Professor Cliff Rosendahl will teach the basics of the ‘chaos and clues’ approach to dermatoscopy in diagnosing melanoma and will demonstrate its practical application to specific cases.

Breakout 4C - MelNet melanoma multi-disciplinary meeting: challenging cases
In this session, a multi-disciplinary panel will discuss the clinical management of a range of challenging or unusual cases of melanoma.

Breakout 4D - Upcoming research and innovations 1
Presenters whose submitted abstracts have been selected will provide snapshots of upcoming research and clinical innovations

Breakout 4E - Patient-led surveillance as a new model of melanoma follow up care
In this session Associate Professor Katy Bell (NHMRC Emerging Leadership Fellow, School of Public Health, University of Sydney) will discuss the MEL-SELF randomised controlled trial which suggests patient-led surveillance in people who have previously been treated for localised melanoma can detect new melanomas more quickly than clinician-led surveillance, and how this new model of patient care could help reduce the burden on health care systems and offer greater convenience for those living further away from treatment centres.

Session 4E kindly sponsored by DermEngine

3:35 pm
3:40 pm

Optional session hosted by Eau Thermale Avène

Sterile Cosmetics: Pure, Gentle, Effective Care for Sensitive Skin is Finally Here
Natalie Wong, National Trainer, Eau Thermale Avène

3:45 pm
4:45 pm

Session 5: Paving the way for high quality, collaborative melanoma care

Waitemata District Health Board: a collaborative skin cancer care model
Dr Daniel Wen, House Officer, Waitemata District Health Board

Nurse led dermatoscopy clinics: the way of the future?
Katy Doherty, Managing Director, Espy Skin, Auckland
Trish Baker, Managing Director, Healthbox NZ Ltd, Auckland

Serious Illness Conversation Guide
Jane Goodwin, Advance Care Planning Facilitator, Health Quality and Safety Commission and Registered Nurse, Canterbury District Health Board

4:45 pm
5.15 pm

Session 6: Concurrent breakout session 2

Breakout 6A - Pathology synoptic reporting and histology update
This session will update on progress towards consistent synoptic reporting for skin cancer.

Breakout 6B - New Zealand melanoma research and therapy special interest group
Intended for those involved or interested in being part of the Melanoma Research and Therapy Special Interest or those with an interest in research or therapy.

Breakout 6C - Upcoming research and innovations 2
Presenters whose submitted abstracts have been selected will provide snapshots of upcoming research and clinical innovations.

Breakout 6D - GPs with a special interest in skin cancer
Intended for those who are part of or interested in joining New Zealand Skin Cancer Doctors. The session will provide an overview of New Zealand Skin Cancer Doctors and the work they do. It will also include a discussion of interesting dermatoscopic and surgical cases. Attendees are encouraged to bring along cases to discuss.
Day 2 Agenda

Second Day

8.30 am
9.00 am

Session 7: Controversy of borderline lesions

Clinico-histological collaboration
Professor Cliff Rosendahl, Course Coordinator of Master of Medicine (Skin Cancer) Programme, University of Queensland, Australia
Dr Ben Tallon, Dermatologist, SKIN Dermatology Institute and Dermatopathologist, Pathlab, Tauranga
Dr Richard Massey, Pathologist and Director, Pathology Associates, Tauranga
Dr Michael Hitchcock, Pathologist and Clinical Lead, Anatomic Pathology Services, Auckland District Health Board

Questions and discussion

9:00 am
10:30 am

Session 8: State of the art melanoma management

My story
Dr Jeff Dalley, Patient representative

In situ melanoma - current best practice in New Zealand
Dr Andrew MacGill, Director, SkinCheck Northcote, Auckland and fully accredited member of New Zealand Skin Cancer Doctors Society 

Mohs surgery for melanoma
Dr Paul Salmon, Dermatologist, Skin Centre Tauranga and Auckland Dermatology

The current role of sentinel node biopsy in managing primary melanoma
Dr Mark Faries, Professor of Surgery and Co-Director Cutaneous Oncology Program, The Angeles Clinic and Research Institute and Cedars-Sinai Medical Center, Los Angeles, USA

Questions and discussion
11:00 am
12:30 pm

Session 9: Advanced melanoma management

My story
Tim Stevens, Patient representative

The future and evolution of adjuvant and neoadjuvant therapy
Dr Inês Pires da Silva, Medical Oncologist and Researcher Scientist at Melanoma Institute Australia, Westmead and Blacktown Hospitals, and University of Sydney

The New Zealand situation
Dr Jody Jordan, Medical Oncologist, Hawke’s Bay District Health Board and Canopy Cancer Care, Hastings

Nurses care perspective on managing advanced melanoma
Jo Tuaine, Oncology Clinical Nurse Specialist, Southern Blood and Cancer Service, Southern District Health Board

Questions and discussion

Session 9 kindly sponsored by MSD
1:30 pm
2:00 pm

Session 10: Melanoma and genetics

Current status of molecular profiling of melanoma
Professor Grant McArthur, Head Molecular Oncology Laboratory, Peter MacCallum Cancer Centre and Executive Director, Victoria Comprehensive Cancer Centre, Melbourne, Australia

Questions and discussion
2:00 pm
2:50 pm

Session 11: Determining New Zealand’s priorities for action

In this session, delegates will be asked to participate in one of three breakout sessions to workshop priorities for action for New Zealand that support primary prevention, early detection, the clinical management of advanced disease and research.

Agreed priorities will be presented to the conference at the conclusion of the session.

2:50 pm
3:45 pm

Session 12: Looking to the future of melanoma

Patient perspective - the final say
Chris and Judy Bailey, Patient representatives
Dr Jeff Dalley, Patient representative
Tim Stevens, Patient representative
Terence Walsh, Patient representative

Wrap up and closing remarks
Mr Gary Duncan and Dr Chris Boberg, Co-Chairs, MelNet

Day 3 Agenda

Third Day